In addition, combined with previous clinical studies, DZXXI increases the activity of SOD and GSH-Px in the renal tissues of patients with diabetic nephropathy and reduces the production of related inflammatory factors IL-6, TNF-α and hs-CRP, inhibit the production of reactive oxygen species and membrane lipid peroxidation and reduce renal inflammation, thereby delaying glomerular sclerosis (Cheng et al., 2007; Li et al., 2011). Here, SOD1 is linked to Glomerular sclerosis.